- Home
- MDU vs CNTA Comparison
MDU vs CNTA Comparison
Compare MDU & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDU | CNTA |
|---|---|---|
| Founded | 1924 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDU | CNTA |
|---|---|---|
| Price | $20.89 | $26.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $22.00 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 1.8M | 1.0M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,875,066,000.00 | N/A |
| Revenue This Year | $6.87 | N/A |
| Revenue Next Year | $5.89 | N/A |
| P/E Ratio | $22.21 | ★ N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $15.04 | $9.60 |
| 52 Week High | $21.49 | $30.58 |
Technical Indicators
Market Signals| Indicator | MDU | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 62.40 |
| Support Level | $20.09 | $21.93 |
| Resistance Level | $21.23 | $30.29 |
| Average True Range (ATR) | 0.42 | 1.11 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 86.48 | 80.04 |
Price Performance
Historical ComparisonAbout MDU MDU Resources Group Inc. (Holding Company)
MDU Resources Group Inc operates in three business segments, which include the electric segment, which generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming; The natural gas distribution segment distributes natural gas in those states, as well as in Idaho, Minnesota, Oregon, and Washington; The pipeline segment provides natural gas transportation and underground storage services through a regulated pipeline system in the Rocky Mountain and northern Great Plains regions of the United States. The majority of its revenues is generated from the Natural Gas distribution segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.